Work Packages

WP 1: Understanding mitochondrial remodelling in NAFLD

Workpackage leader: CNR

The involved activates will contribute to the suitable characterization of mitochondrial function and biogenesis during NAFLD progression. The ultimate goal is to develop advanced methodology: i) to isolate functional mitochondria from NAFLD cells and tissues, and ii) to improve mitochondrial storage, technical support to roadmap the hepatic Krebs cycle fluxes, design analytical ELISA-based methodology to measure p66Shc activation in blood cell samples in NAFLD condition and improved techniques to assess pro-inflammatory extracellular mitochondrial components in NAFLD. 

WP 2: Development of novel biomarkers and innovative non-invasive strategies for NAFLD assessment

Workpackage leader: MEDIAGNOST

WP2 will produce a novel biomarkers and innovative non-invasive strategies for better assessment of NAFLD disease, through the amelioration of 13C-breath tests. Implementing these new biomarkers for predicting the risk of postoperative hepatic failure (PHF). Identifying new molecular targets that may contribute to the pathogenesis of inflammatory liver diseases progressing to hepatocellular carcinoma and clarify the therapeutic potential of specific miRNAs. It is planed to establish new ELISA based assays to detect proteins in circulation as a diagnostic kit that can be used in the clinical practice etc. 

WP 3: Validate the predictive potential of the newly-identified biomarker

Workpackage leader: UNIBA

WP3 will involve mitochondrial antioxidant therapy, where new NAFLD therapeutic solutions based on mitochondrial-directed dietary antioxidants will be developed. The end goal of producing this drugs is to be introduced into the pharmaceutical market. Objective of WP3 is also to test different dietary approaches for NAFLD treatment, where the novel ELISA-based test developed at WP2, and mid-range IR-based detection of metabolites in plasma will be used to detect whether the supplementary olive oil/mushrooms consumption improve mitochondrial function in liver. The efficiency of physical exercise will be evaluated in reducing the NAFLD phenotype in high fat diet rodents and patients.

WP 4: Exploitation and Dissemination & Communication

Workpackage leader: CNC

WP4 will organize meetings, seminars, workshops, networking events, seminar series etc. It will use various communication channels and tools to implement different exploitation strategies targeting specific groups, (policymakers, scientists, industry, patient associations, children etc.). Production of the project dissemination materials to familiarize the general public with strategy to prevent and combat the NAFLD disease etc. 

WP 5: Overall Project Management

Workpackage leader: CNC

Management activates aim to ensure the successful and timely achievement of project goals. WP5 establishes a comprehensive FOIE GRAS coordination and management through careful planning and efficient and correct operational, administrative and financial management and interaction with the European Commission. It will monitor the progress of each WP and planning, core progress control and technical evaluation of secondments progress. Set up internal communication among consortium and guarantee timely organisation and performance of activities and project meetings.

WP6: Ethics requirements

Workpackage leader: CNC

The objective of WP6 is to ensure project compliance with the relevant 'ethics requirements'. Such as requirements consist of essential safety copies of ethics approvals for the research involving humans, copies of relevant authorisations (for breeders, suppliers, users, and facilities) for animal experiments, copy of project authorisation (covering also the work with genetically-modified animals, if applicable), copies of training certificates/personal licenses of the staff involved in animal experiments etc.